RepublicanBill · S. 2292· Senate(119-S-2292)

Over-the-Counter Monograph Drug User Fee Amendments

Rep. Banks
Age: 47 years
Indiana
Introduced
7/15/2025
Last activity
9/8/2025 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.
Sponsored by
Jim Banks
Cosponsors
Republican - 1Democrat - 2
Health
  1. Introduced
  2. On Calendar

What this bill would do

This bill amends the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter (OTC) monograph drugs. It establishes new fee structures, due dates, and revenue amounts for fiscal years 2026 through 2030. The legislation also updates definitions regarding testing procedures and provides new standards for evaluating active ingredients for topical administration. Additionally, it creates a process for "Rx-to-nonprescription switches" to increase predictability for drug developers. Finally, the bill mandates various reporting requirements and GAO assessments regarding the drug supply chain and application processes.

Yes

  • Does this make what the government does easier for the public to see?+6

    The bill requires the publication of negotiation meeting minutes and annual performance reports to increase transparency.

  • Does this give people more protection from unfair business practices?+5

    The bill enhances consumer protection by increasing transparency in FDA negotiations and improving oversight of the OTC drug supply chain.

  • Does this make health care easier to get in general?+3

    The bill aims to improve access to medications by streamlining the process for prescription-to-OTC switches.

The opposite

  • Would business owners be better off under this?-3

    The bill imposes new facility fees and potential workload adjustments on drug developers and manufacturers.